Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
Jan Styczyński,Gloria Tridello,Linda Koster,Simona Iacobelli,Anja van Biezen,Steffie van der Werf,Małgorzata Mikulska,Lidia Gil,Catherine Cordonnier,Per Ljungman,Diana Averbuch,Simone Cesaro,Rafael de la Camara,Helen Baldomero,Peter Bader,Grzegorz Basak,Chiara Bonini,Rafael Duarte,Carlo Dufour,Jurgen Kuball,Arjan Lankester,Silvia Montoto,Arnon Nagler,John A. Snowden,Nicolaus Kröger,Mohamad Mohty,Alois Gratwohl,
DOI: https://doi.org/10.1038/s41409-019-0624-z
2019-08-27
Bone Marrow Transplantation
Abstract:Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980–2001) to cohort 2 (2002–2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of "unknown origin".
oncology,immunology,hematology,transplantation